Richard M. Zweig
LSU Health Sciences Center Shreveport
18 Papers
35 Citations
Richard M. Zweig is an academic researcher from LSU Health Sciences Center Shreveport. The author has contributed to research in topics: Medicine & Dopaminergic. The author has an hindex of 12, co-authored 17 publications. Previous affiliations of Richard M. Zweig include Louisiana State University & Louisiana State University in Shreveport.
Chat about Author
Papers
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Christopher G. Goetz,Barbara C. Tilley,Stephanie R. Shaftman,Glenn T. Stebbins,Stanley Fahn,Pablo Martinez-Martin,Werner Poewe,Cristina Sampaio,Matthew B. Stern,Richard Dodel,Bruno Dubois,Robert G. Holloway,Joseph Jankovic,Jaime Kulisevsky,Anthony E. Lang,Andrew J. Lees,Sue Leurgans,Peter A. LeWitt,David L. Nyenhuis,C. Warren Olanow,Olivier Rascol,Anette Schrag,Jeanne A. Teresi,Jacobus J. van Hilten,Nancy R. LaPelle,Pinky Agarwal,Saima Athar,Yvette Bordelan,Helen Bronte-Stewart,Richard Camicioli,Kelvin L. Chou,Wendy Cole,Arif Dalvi,Holly Delgado,Alan Diamond,Jeremy P.R. Dick,John E. Duda,Rodger J. Elble,Carol Evans,V. G. H. Evidente,Hubert H. Fernandez,Susan H. Fox,Joseph H. Friedman,Robin D. Fross,David A. Gallagher,Deborah A. Hall,Neal Hermanowicz,Vanessa K. Hinson,Stacy Horn,Howard I. Hurtig,Un Jung Kang,Galit Kleiner-Fisman,Olga Klepitskaya,Katie Kompoliti,Eugene C. Lai,Maureen L. Leehey,Iracema Leroi,Kelly E. Lyons,Terry McClain,Steven W. Metzer,Janis M. Miyasaki,John C. Morgan,Martha Nance,Joanne Nemeth,Rajesh Pahwa,Sotirios A. Parashos,Jay S. Schneider,Kapil D. Sethi,Lisa M. Shulman,Andrew Siderowf,Monty Silverdale,Tanya Simuni,Mark Stacy,Robert Malcolm Stewart,Kelly L. Sullivan,David M. Swope,Pettaruse M. Wadia,Richard Walker,Ruth H. Walker,William J. Weiner,Jill Wiener,Jayne R. Wilkinson,Joanna M. Wojcieszek,Summer C. Wolfrath,Frederick Wooten,Allen Wu,Theresa A. Zesiewicz,Richard M. Zweig +87 more
TL;DR: The combined clinimetric results of this study support the validity of the MDS‐UPDRS for rating PD.
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Tanya Simuni,Karl Kieburtz,Barbara C. Tilley,Jordan J. Elm,Bernard Ravina,Debra Babcock,Marina E. Emborg,Robert A. Hauser,Cornelia Kamp,John C. Morgan,G. Webster Ross,David Simon,Jacci Bainbridge,Liana Baker,Ivan Bodis-Wollner,James T. Boyd,Franca Cambi,Julie H. Carter,Kelvin L. Chou,Nabila Dahodwala,Richard B. Dewey,Rohit Dhall,John Y. Fang,Buff Farrow,Andrew Feigin,Sofya Glazman,John L. Goudreau,Pauline LeBlanc,Stephen L. Lee,Maureen A. Leehey,Mark F. Lew,Stephanie Lowenhaupt,Sheng Luo,Rajesh Pahwa,Adriana Pérez,Jay S. Schneider,Burton L. Scott,Binit B. Shah,Kathleen M. Shannon,Saloni Sharma,Carlos Singer,Daniel D. Truong,Renee Wagner,Karen Williams,Anne-Marie Wills,Pei Shieen Wong,Pei Shieen Wong,Cindy Zadikoff,Richard M. Zweig +48 more
TL;DR: It is suggested that pioglitazone at the doses studied here is unlikely to modify progression in early Parkinson's disease.
Sex specific cognitive differences in Parkinson disease.
Tyler H. Reekes,Christopher Ian Higginson,Christina Ledbetter,Niroshan Sathivadivel,Richard M. Zweig,Elizabeth A. Disbrow +5 more
TL;DR: The data indicate that males with PD have significantly greater executive and processing speed impairments compared to females despite no differences in demographic variables or other measures of disease severity.
111
Novel suppressors of α-synuclein toxicity identified using yeast
Jun Liang,Cheryl Clark-Dixon,Shaoxiao Wang,Todd R. Flower,Tara Williams-Hart,Richard M. Zweig,Lucy C. Robinson,Kelly Tatchell,Stephan N. Witt +8 more
TL;DR: Four of the five genes are specific for α-syn in that they fail to protect cells from the toxicity of the two inherited mutants A30P or A53T, which suggests that α- syn causes toxicity to cells through a different pathway than these two inherit mutants.
61
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.
Robert A. Hauser,Ruosha Li,Adriana Pérez,Xuehan Ren,Dan Weintraub,Jordan J. Elm,John L. Goudreau,John C. Morgan,John Y. Fang,Michael J. Aminoff,Chadwick W. Christine,Rohit Dhall,Chizoba C. Umeh,James T. Boyd,Natividad Stover,Maureen A. Leehey,Richard M. Zweig,Anthony P. Nicholas,Ivan Bodis-Wollner,Allison W. Willis,Karl Kieburtz,Barbara C. Tilley +21 more
TL;DR: Findings support the possibility that MAO-B inhibitors slow clinical disease progression and suggest that a definitive prospective trial should be considered.
28